Evidence map›Paper›PMID 41724771›Full record

ArticleScientific reports2026

GCIPL color coding on OCT predicts glaucoma conversion in normal-tension glaucoma suspects, including a high myopia subgroup.

Hee Jong Shin, Hae-Young Lopilly Park, Hee Kyung Ryu, Chan Kee Park

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hee Jong ShinDepartment of Ophthalmology, The Catholic University of Korea, Seoul, South Korea.
Hae-Young Lopilly ParkDepartment of Ophthalmology, The Catholic University of Korea, Seoul, South Korea. lopilly@catholic.ac.kr.
Hee Kyung RyuDepartment of Ophthalmology, The Catholic University of Korea, Seoul, South Korea.
Chan Kee ParkDepartment of Ophthalmology, The Catholic University of Korea, Seoul, South Korea.

Funding

National Research Foundation of Korea NRF-2021R1A2C2093617
6 · The paper itself

Abstract

This retrospective study investigated the predictive value of OCT-derived color coding in assessing the risk of glaucoma conversion among normal-tension glaucoma (NTG) suspects, with a particular focus on highly myopic eyes. A total of 307 eyes underwent baseline spectral-domain OCT imaging, with RNFL and GCIPL thicknesses categorized by device-generated color codes (green: normal, yellow: borderline, red: abnormal). Glaucoma conversion was defined by the emergence of reproducible visual field defects over a mean follow-up of 76.0 ± 8.8 months, during which 23.8% of eyes progressed. Inferotemporal GCIPL thickness showed the strongest discriminative capacity (AUC = 0.68, cutoff = 62.0 μm), with further improvement in highly myopic eyes (AUC = 0.85). Red color coding in the inferotemporal sector was associated with a significantly increased risk of conversion (HR 2.473; p = 0.050), while eyes with green coding in both inferotemporal and average GCIPL sectors demonstrated high negative predictive values (85.0% overall, 90.2% in the myopic subgroup). These results highlight the clinical utility of GCIPL color coding on OCT as an accessible and practical tool for identifying early disease stability and stratifying risk of progression, even in anatomically challenging high myopia cases.

Indexed as

GlaucomaLow Tension GlaucomaMyopiaTomography, Optical CoherenceAgedDisease ProgressionFemaleHumansMaleMiddle AgedRetrospective StudiesVisual FieldsColor code classificationGanglion cell-inner plexiform layer (GCIPL)Glaucoma progressionNormal tension glaucoma

Identifiers

PMID41724771
PMCPMC13022368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.